NCT03470922 2025-09-09RELATIVITY-047Bristol-Myers SquibbPhase 2/3 Active not recruiting714 enrolled 17 charts 1 FDA
NCT03212404 2025-02-03Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersCheckpoint Therapeutics, Inc.Phase 1 Active not recruiting272 enrolled 1 FDA